Introducing…the Medicines Manufacturing Industry Partnership
Posted on 09/09/16
Thanks to everyone who came along to BioGateway’s breakfast meeting on MMIP. The event, held in partnership with Discovery Park, confirmed the huge potential of the kind of ground-breaking research taking place right here on site.
This was the latest in a series of science focused breakfast sessions organised by BioGateway, Kent’s network for Life Science companies and focused on work being done to promote the growth of medicines manufacturing.
The main thrust of the session was to explain the work of the Medicines Manufacturing Industry Partnership, set up to give a single voice to the sector from Big Pharma down to smaller and medium sized SMEs. It links a number of key member organisations including abpi, BIA and KTN
MMIP Project manager, Neil Baker (second from left), who also works for Pfizer, set the scene for the creation of the organisation in 2014 and the challenges and opportunities – not only for individual companies but for the UK as a whole.
The partnership, he explained, was established to bring the UK’s medicines manufacturing industry together to create an attractive and innovation rich environment to drive UK competitiveness and build international recognition.
Its work, the meeting heard, centred on a number of areas, but with a focus on attracting more people into science; powered with the rights skills to retain and grow the UK’s place as a key global centre for science research.
The regulatory framework faced by science companies of all sizes, particularly in a post Brexit environment, and support needed for business to go from academic idea through to commercialisation also loom large in MMIP’s in-tray.
It was great to see two of the pharmaceutical industry’s biggest names represented in the room with Gregor Anderson Director of Device Design at GSK following Neil with some of the technological based initiatives being explored by MMIP and moves towards closer links with academia.
Part of the job in hand, the meeting heard, was to get a better understanding of data available to help the industry to identify gaps and alleviate bottlenecks in the manufacturing process. The ultimate aim – to grab a real opportunity for Britain to lead the way.
Magda Papadaki, the final speaker of the morning, said the future for science research in the UK lay in advanced therapies – from tissue engineering and bio-synthetic materials and devices to the immunotherapeutic approaches to disease – the kind of work taking place right now at Discovery Park.
Imran Khan, CEO for BioGateway, said:
“It’s important Kent’s science community is engaged with the ever changing health life science landscape, to ensure our members are aware of the opportunities and the challenges that may impact their organisation. The work done by the MMIP is credit to the industry and presents an opportunity to drive innovation and collaboration across the industry.”
To find out about BioGateway, visit www.thebiogateway.org